🤩 Finally OUT in @JCO_ASCO! BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy A decade of persistence from @VedangMurthy ☺️ @RadOncTMC @TataMemorial @ACTREC_TMC @PaulSargos @Xristodouleas ascopubs.org/doi/full/10.120…

Priority Editorial! When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era by Martino Pedrani et al Read the full article: buff.ly/n6uKXj0 We thank the authors for their insight. @PedraniMartino @DeGiorgiAlberto @AndreaGallina5 @UrsulaVogl @ZilliThomas @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

In which patients is metastases-directed therapy without systemic therapy sufficient? Presentation by @KOSJ12 @MoffittNews. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4umwR3E @APCCC_Lugano

New IBCG consensus: Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group (IBCG) Full text: authors.elsevier.com/a/1mf5C… @shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

Congrats @JJCaudell @BeekeepRadOnc @DrKedarKirtane @CHChungMD on this novel phase II trial personalizing radiation dose for HPV oropharyngeal cancer using PSI @MoffittNews @MoffittRadOnc

We’ve treated polymetastatic disease as “too much” for RT for decades. Our new review in @IJROBP dives into the practical realities of treating widespread disease with SABR immunomodulatory LDRT - from patient selection to workflows that scale. @MoffittNews @drdavidpalma

Congrats!!

FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer | FDA@ great news for our patients ⁦@MayoClinic⁩ ⁦@shilpaonc⁩ ⁦@PGrivasMDPhD⁩ fda.gov/drugs/resources-info…

From #ASTRO25: Kosj Yamoah, MD (@KOSJ12), shared findings on the Decipher genomic classifier and Artera multimodal AI biomarker in predicting metastasis in localized prostate cancer. Both outperform traditional risk tools. Key findings: ➡️ In 306 prostate cancer cases, Decipher and Artera scores showed only weak overall correlation. ➡️Each was independently linked to distinct biological pathways in metastatic patients. ➡️Together, they may offer complementary value in defining aggressive disease. learn more: amportal.astro.org/sessions/… #MoffittASTRO25

Awesome work @NakashimaJustyn! One of our chiefs @MoffittRadOnc soon to provide excellent care to many patients in the Orlando area 💪🏻

At the #ASTRO25 plenary session, Vedang Murthy, MD, (@VedangMurthy @TataMemorial) shares clinical outcomes of adjuvant radiotherapy (RT) after radical cystectomy (RC) and chemotherapy in locally advanced muscle-invasive bladder cancer (LA-MIBC). ➡️ Adjuvant RT improved LRFS and DFS without increased severe late toxicity in patients with LA-MIBC post cystectomy and chemotherapy. ➡️ Potential benefit in OS is being explored in a planned individual patient data meta-analysis of randomized trials. Read more: amportal.astro.org/sessions/… #MoffittASTRO25 @ASTRO_org

Strong 💪🏻 work from a stellar resident @celinachiodo presenting @MoffittNews early experience with online hypofx adaptive bladder radiation. Awesome support by @MoffittRadOnc physics in making this an option for our patients

Incredibly honored to be 1 of 12 residents in the country to receive a Recognition Meeting Abstract Award for our work on Adaptive Radiotherapy for Locally Advanced Lung Cancer. So thankful for my mentors and Moffitt Cancer Center for supporting our research. #ASTRO25

Great job @DK_18621 presenting your research on the use of ctDNA in post-TMT surveillance. Much to learn with this data. 🚨 Rising ⭐️ @MoffittRadOnc @MoffittNews

HOT OFF THE PRESS! Neoadjuvant PAE prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation - ctro.science/article/S2405-6… @MoffittNews @MoffittRadOnc @KOSJ12 @gdgrass @VaseemKhatri @ctRO_journal

I often hear that post-TMT cystectomy is “fraught with complications even in experienced hands.” That hasn’t been my experience. With the right principles and disciplined technique, these cases can be remarkably straightforward. Maybe I’m delusional - but curious to hear what others think. What’s been your experience? @siadaneshmand @drgaganprakash @joanfundi @bbmdmsk @UrogerliMD @MarekBabjuk @MariaJRibal @AlisonBirtle @ParamMariappan @LauraBukavinaMD @SimaPorten @nnavai @MaxKates @SpiessPhilippe @paolo_gontero @VedangMurthy #OncSurgery @MRoupret @garysteinbergmd

Radiation vs systemic therapy for isolated pelvic recurrence after cystectomy. @UroDocAsh moderates a debate between @AndreaNecchi @SanRaffaeleMI & Comron Hassanzadeh, MD, MPH @MDAndersonNews. Comron Hassanzadeh backs pelvic radiation for isolated recurrence, while Andrea Necchi highlights systemic therapy with EV-pembro and data from EV-302 & CheckMate-901. Both stress the importance of biomarkers, patient input & multidisciplinary care. 🎥 #WatchNow > bit.ly/3TdQBpF

Strong work @ninaobertopp & @MoffittNews Pilon-Thomas lab on how 8 Gy x 1 may open options for RT-cellular therapy integration! @MoffittRadOnc @RRS_RadRes @QuadShotNews Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-... sciencedirect.com/science/ar…

Cystectomy vs. Bladder Preservation: Weighing Options for Muscle-Invasive Bladder Cancer #MIBC. @BogdanaSchmidt @huntsmancancer & @mouwlab @DanaFarber join @UroDocAsh @MDAndersonNews in a debate on treatment options for muscle-invasive bladder cancer. #WatchNow on UroToday > bit.ly/3IfeTxj

Results from our Ph II multi-institutional study now out in @IJROBP redjournal.org/article/S0360… Overall & objective responses noted in PD-L1 neg metastatic cervical ca with use of SBRT and atezo. Collaboration between @MoffittRadOnc @MoffittGYNONC @OhioStateRadOnc 🤝 @OncoAlert